Other Financings Of Public Biotechnology Companies: April 2002
Total: $1,045.1M | ||||
Company (Symbol)# | Type Of Financing | Number Of Shares, Units Or Warrants (M) | Amount Raised (M) | Investors; Placement Agents; Details (Date)@ |
AEterna Laboratories Inc. (AELA; TSE:AEL) | Private placement of common stock and warrants | 7.57S and 7.43W | C$57 | AEterna raised US$35.7M in two private placements, one with SGF Sante and Solidarity Fund QFL, and the other with Acqua Wellington Private Placement Fund Ltd.; the first one involved 7.3M shares and 7.3M warrants; the second one involved about 270,000 shares and about 133,000 warrants (4/9) |
Allos Therapeutics Inc. (ALTH) | Private placement of common stock | 2.5S | $15 | Allos raised $15M in a private placement with Perseus-Soros Pharmaceutical Fund LP (4/24) |
Bioniche Pharma Group Ltd. (unit of Bioniche Life Sciences Inc.; Canada; TSE:BNC) | Private placement of a convertible debenture | N/A | C$1.8 | Bioniche Pharma received US$1.1M from ICC Venture Capital in the form of a 6% convertible debenture (4/24**) |
Biopure Corp. (BPUR) | Private placement of common stock | 2.8S | $20.7 | Biopure raised about $20.7M with the placement of 2.8M shares with institutional investors (4/24) |
Genaera Corp. (GENR) | Private placement of common stock | 6S | $16.5 | Genaera raised $16.5M in a private placement with institutional investors (4/9) |
Hyseq Pharmaceuticals Inc. (HYSQ) | Private placement of common stock | 3.58S | $15 | Hyseq raised $15M in a private placement with undisclosed accredited investors (4/9) |
IDEC Pharmaceuticals Corp. (IDPH) | Private placement of senior convertible notes | Convertible into 8.2S | $675 | IDEC expects to gross $675M with the placement of notes that are convertible into 8.2M shares, or 9.1M shares if the overallotment option is exercised in full; the notes were offered to institutional buyers (4/24) |
Isis Pharmaceuticals Inc. (ISIP) | Private placement of convertible subordinated notes | ND | $125 | Isis raised $125M in the placement of notes, which are convertible into shares at $16.625 per share (4/26) |
Ligand Pharmaceuticals Inc. (LGND) | Private placement of common stock | 4.25S | $69.3 | Ligand raised $69.3M in a private placement of 4.25M shares (4/17) |
Lynx Therapeutics Inc. (LYNX) | Private placement of common stock | 14.6S and W for 5.8S | $22.6 | Lynx raised $22.6M in a private placement of 14.6M shares, as well as warrants for 5.8M shares (4/18) |
Nymox Pharmaceuticals Corp. (NYMX) | Private placement of common stock | N/A | $0.819 | Nymox raised $819,000 through a private placement with existing shareholders (4/3) |
Senesco Technologies Inc. (OTC BB: SENO) | Private placement of common stock and warrants | N/A | $3.48 | Senesco raised $3.48M through a private placement with certain accredited investors (4/24) |
Versicor Inc. (VERS) | Private placement of common stock | 3S | $44.9 | Versicor raised $44.9M in a private placement (4/11) |
Notes: | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. This chart does not include real estate or manufacturing plant financings. | ||||
@ Dates refer to the date of the press release. | ||||
** Denotes the date the item ran in BioWorld International. | ||||
N/A = Not available, applicable or reported. | ||||
OTC BB = Over the Counter Bulletin Board; TSE = Toronto Stock Exchange | ||||